Radium-223 (or Alpharadin) is a new targeted alpha-emitting agent which has shown a prolongation of survival in castrate-resistant prostate cancer patients with bone-metastatic disease (5). 

Without an understanding of your medical records, you are likely to research the term “prostate cancer” alone, which can lead to a bottomless well of impersonal information. With some understanding of your records, you will learn to research prostate cancer in context of your own biology – your own pathology, PSA pattern, imaging results, and prostate size, to name a few factors.